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Abstract
In vivo bioavailability studies are performed for new drug to establish essential 
pharmacokinetic parameters including rate of absorption, extent of absorption, 
rates of excretion and metabolism and elimination half-life after a single and 
multiple dose administration. These essential pharmacokinetic parameters are 
useful in establishing dosage regimens. Bioequivalence used to assess the expected 
in vivo biological equivalence of two proprietary preparations of drug products. 
If two drugs are bioequivalent, it means that they are expected to be same for all 
intents and purposes. In determining bioequivalence between two drugs such as 
a reference drug or brand and potential to be test drug or marketed generic drug. 
Pharmacokinetic studies are conducted whereby each of the drugs is administered 
in a cross over study to healthy volunteer’s subjects. Plasma is obtained at regular 
intervals and assayed for parent drug or metabolite concentration to compare the 
two drugs. For comparison purpose of two formulations, the plasma concentration 
data are used to assess key pharmacokinetic parameters. If 90% confidence interval 
for the ratio of the geometric least square means of peak plasma concentration, area 
under curve of test and reference drugs are within 80–125%, then bioequivalence 
will be established.
Keywords: bioavailability, bioequivalence studies, pharmacokinetic parameters, 
cross over study, area under curve
1. Introduction
Bioavailability is defined as relative amount of drug from an administered dos-
age which enters the systemic circulation and the rate at which the drug appears in 
the systemic circulation. The bioavailability studies are done by measuring the con-
centration of the drug in the plasma or blood after administration of drug following 
systemic protocol of studies and documented over time. The systemic protocol is 
helpful for clinical trials in the early drug development, and the data obtained are 
used in subsequent bioequivalence studies. Bioequivalence studies were carried out 
to distinguish between two pharmaceutical products containing the same active 
substance. One drug formulated into two different formulations if they show to be 
therapeutically equivalent to one another in order to be considered interchangeable.
Pharmacokinetics of drug deals with the change in drug concentration in plasma 
and/or its metabolites in the human or animal body with respect to time following 
administration of the pharmaceutical product. Bioequivalence studies are used to 
assess the expected in vivo biological equivalence of two proprietary preparations 
of a drug. If two pharmaceutical products are said to be bioequivalent, then they 
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would be expected to be the same for all intents and purposes. Bioequivalence of 
a drug product is achieved if its extent and rate of absorption are not statically 
significantly different from those of reference product when administered at the 
same molar dose. If the bioavailability of two formulations administered in the 
same molar dose is similar, then they are said to be bioequivalent [1–10]. Different 
test methods are available to assess equivalence, including:
1. Comparative bioavailability studies, in which the active drug substance is 
measured in an accessible biological fluid such as plasma
2. Comparative clinical trials
3. Comparative pharmacodynamic studies in humans
Bioavailability and bioequivalence studies are required to ensure therapeutic 
equivalence between a pharmaceutically equivalent test drug and a generic drug 
or reference drug. Ensuring uniformity in standards of quality, efficacy, and 
safety of pharmaceutical products is the fundamental responsibility of central 
drugs standard control organization (CDSCO) [11]. Bioequivalence has to be 
considered for various products containing active ingredients marketed under 
different licensees are clinically equivalent and interchangeable. Submission of 
application for new drugs under schedule Y should be required to furnish the 
bioavailability and bioequivalence data, that is, mainly focus on the drug release 
from the pharmaceutical dosage form and subsequent absorption into the sys-
temic circulation.
Comparative bioavailability or relative bioavailability refers to a comparison 
of two pharmaceutical dosage forms in terms of their relative rate and extent of 
absorption. In some cases, two pharmaceutical formulations exhibit markedly 
different bioavailability, for example, a rapidly absorbed elixir and more slowly 
absorbed capsule. In other cases, two different dosage formulations such as tablet 
and a capsule may or may not exhibit very similar bioavailability [12].
  Comparative bioavailability =  
AUCpo × Doseiv
  _____________
AUCiv × Dosepo
. (1)
Absolute bioavailability refers to an active pharmaceutical ingredient reach-
ing the systemic circulation and fraction of drug absorbed ranges from 0 to 1. If 
F is zero, it means no drug absorptions, and the drug is completely absorbed in 
the systemic circulation if F = 1. The total amount of drug reaching the systemic 
circulation is directly proportional to the area under curve (AUC), and fraction of 
drug absorbed is determined by comparing the respective AUCs of the test product 
and the same dose of the drug administered intravenously [13].
  Absolute bioavailability =  
AUCpo
 ______
AUCiv
 (2)
1.1 Types of studies required in bioequivalence studies
For certain drugs, in vivo equivalence was done through either a bioequivalence 
study or a comparative clinical pharmacodynamic study. For oral immediate drug 
release formulations with systemic action have one or more adverse conditions 
like narrow therapeutic window, steep dose-response curve, nonlinear pharma-
cokinetics, presystemic elimination, unfavorable physicochemical properties. 
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Physicochemical properties such as solubility and instability of the drug, metastable 
transformation, poor permeability, etc., are bioavailability problems related to the 
drug or drugs having similar chemical structure or formulations, where a high ratio 
of excipients to active ingredients exists. Drugs administered other than oral and 
parenteral formulations design act by systemic absorption, sustained release drug 
formulations design act by systemic absorption, fixed dose combination products 
with systemic action, nonsolution pharmaceutical products which are for nonsys-
temic use and intended act without systemic absorption are also studied.
In these cases, the bioequivalence concept is not suitable, and then compara-
tive clinical or pharmacodynamic studies are required for proving equivalence. 
Bioequivalence studies are used to establish links between the early and late clinical 
trial formulations, formulations used in clinical trials and stability studies, clinical 
trial formulations and to be marketed drug products. In each comparison, the new 
formulation or new method of manufacture shall be the test drug, and the prior 
formulation shall be considered as the reference drug.
1.2 When no need of bioequivalence studies
In some formulations, bioequivalence studies are not required if bioequivalence 
between a test drug and a reference drug may be considered self-evident with no 
further requirement for documentation such as when a gas is in the form of test drug, 
when test drugs are to be administered parenterally such as subcutaneous, intramus-
cular, intravenous, etc. as aqueous solution and contain the same drug in the same 
concentration and the same excipients in comparable concentrations. Bioequivalence 
studies are not required for when the test drug is in the form of solution for oral use 
and contains the drug in the same dose and does not contain an excipient that is 
known to affect gastro-intestinal absorption of the drug; when the test drug is in the 
form of an ophthalmic or topical product prepared as aqueous solution and contains 
the same active ingredients in the same concentrations and essentially the same 
excipients in comparable concentrations when the test drug is in the form of powder 
for reconstitution as a solution and the solution meets either above second and third 
points, when a test drug is in the form of an inhalation or a nasal spray tested by 
administered with or without the same device used for reference drug.
2. Design and conduct of pharmacokinetic studies
2.1 Study object
The object of the bioavailability study decides the study protocol. A study 
protocol used for estimating pharmacokinetic parameters is different from a 
bioequivalence study carried out for comparing the test formulation with standard 
formulation.
2.2 Study design
The main object of the experimental design is to minimize the experimental 
variables and to avoid a bias [14]. In vivo bioavailability study is determined by 
taking into consideration of the following points:
1. The nature of the reference drug and the dosage form to be tested
2. Benefit risk ratio considerations in regard to testing in humans
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3. The availability of analytical methods
4. What is the scientific questions to be answered
Bioavailability studies are influenced by various factors such as age, sex, disease 
state, food habits, physical and mental health condition, body weight human vol-
unteer, experimental design, time of administration, time of sampling, analytical 
method used and compartment model used in estimating pharmacokinetic parame-
ters or bioavailability that contribute to the observed blood concentration time profile. 
Therefore, it is necessary to consider all these important factors in a study design.
The bioavailability study should be designed in such a way that the formulation 
effect can be distinguished from other effects. If two formulations are to be com-
pared, a two-period, two-sequence crossover design is the design of choice which 
should ideally be equal to or more than five half-lives that have to be measured. 
Alternative study designs include the parallel design for very long half-life sub-
stances with highly variable disposition [15].
In the following sections, various factors are discussed keeping the bioequivalence 
study also in mind. However, they are valid for simple bioavailability studies also.
2.2.1 Parallel design
In a parallel design, two formulations are administered to two groups of volun-
teers. To avoid a bias, formulations may be administered randomly to the volun-
teers. The major disadvantage of this design is that the intersubject variation is not 
being corrected. It has been proved beyond doubt that most of the times intersub-
ject variation is greater than the variation between any formulation. Therefore, 
a cross over design is preferred in bioavailability or bioequivalence trails to avoid 
influence of a intersubject variation. This design is used mainly for drug, and its 
metabolites have long elimination half-life. The carryover effects or dropouts were 
less in parallel studies compared to crossover studies.
2.2.2 Crossover design
As recommended by the USFDA [7], in most bioequivalence studies, a test 
drug is compared with the standard reference drug in a group of normal healthy 
subjects of age 18–55 years, each receives both the treatments alternately, in a 
crossover fashion (two-period, two-treatment crossover design), with the two 
phases of treatment separated by a washout period of generally a week’s duration 
and it mainly depends on the half-life of the drug [16]. If elimination half-life of 
the drug increases, the washout period also increases. The drug formulation either 
test or reference is given to each human volunteer randomly but an equal number of 
subjects receives each treatment in each period, as given in Table 1. In case of two 
treatments, groups 1 and 2, one group receives the treatment in the order A and B, 
and the second group receives in the reverse order B and A. A similar allocation is 
done in case of a three-treatment crossover design (three-period, three-treatment 
crossover design). Intersubject variability is observed for several drugs in clearance. 
The intrasubject coefficient of variation (approximately 15%) is usually substan-
tially smaller than that between subjects (approximately 30%), and therefore 
crossover designs are generally recommended for bioequivalence studies.
In crossover design, the treatments are compared on the same human subject, 
and the intersubject variability is reduced. Both the designs depend on the three 
fundamental statistical concepts of study design, and these are randomization, 
replication, and error control. Randomization means allocation of treatments to the 
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subjects without bias. Replication involves the application of more than one experi-
mental subject for reliable estimates than a single observation and also provides a 
more precise measurement of treatment effects. The number of replicates required 
mainly depends upon the degree of differences to be detected and inherent variabil-
ity of the data. Commonly used cross over designs in bioavailability trails are Latin 
square cross over design and balanced incomplete block design.
A standard approach for conducting a comparative bioavailability study to use a 
randomized, balanced, cross over design called Latin square or complete cross over 
design is as shown in Table 1. Incomplete block design (BIBD) eliminates many 
of the difficulties encountered with the Latin square design. In this, each subject 
receives not more than two formulations, each formulation is administered the same 
number of times and each pair of formulations occurs together in the same number 
of subjects. Table 2 shows BIBD four formulations A, B, C, and D. In this design, as 
discussed above, each subject receives two formulations, each formulation is admin-
istered six times and each pair of formulations occurs together in two subjects (the 
pairs are AB, AC, AD, BC, BD, and CD).
2.3 Washout period
In a Latin square cross over design, each subject receives each formulation, and 
even in BIBD, each subject receives two formulations at different occasions. The 
time interval between the two treatments is called “washout period.” Washout 
period is required for the elimination of the administered dose of a drug so as to 
avoid the carryover. For most of drugs in crossover design, at least 10 half-lives 
should be allowed between treatments. This should ensure an elimination of 99.9% 
of the administered dose and a maximum carryover of less than 0.1% from first 
treatment. The number of washout period is a function of the half-life and the dose 
of the drug administered. The number of washout periods in a study depends upon 
the type of crossover design used and the number of formulations to be evaluated. 
Group No. Subject in group Treatment for period No.
Two-way crossover
I II
1. 1, 2, 3, 4, 5, 6 A B
2. 7, 8, 9, 10, 11, 12 B A
Three-way crossover
I II III
1. 1, 2, 3, 4, 5, 6 A C B
2. 7, 8, 9, 10, 11, 12 B A C
3. 13, 14, 15, 16, 17, 18 C B A
Four-way crossover
I II III IV
1. 1, 2, 3, 4, 5, 6 A B C D
2. 7, 8, 9, 10, 11, 12 B D A C
3. 13, 14, 15, 16, 17, 18 C A D B
4. 19, 20, 21, 22, 23, 24 D C B A
Table 1. 
Latin square design.
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In case of digitoxin, which has a half-life of 6–9 days, the total study period exceeds 
1 year if four formulations have to be evaluated using Latin square design. Because 
a very large number of drugs have been found to have half-lives between 1 and 
10 hours, a washout period of 1 week was usually found suitable in most of the 
reported studies. It should be noted that the metabolites of the drug should also be 
eliminated from the body before the commencement of next treatment.
2.4 Drug product and reference standard
Test product may be new drug formulations developed by pharmaceutical tech-
nologists or new dosage forms of an existing drug. A test product may be compared 
to a reference standard recognized by the Food and Drug Administration for getting 
approval for marketing the drug product. Test product are generally evaluated 
to select best dosage form of a new drug or existing drug among different dosage 
forms, to select the best formulation of a new drug or existing drug among differ-
ent formulations that have shown equal performance in vitro tests and to compare 
biological performance of a test product to that of a recognized standard [17, 18].
A generic product has to compare with some standard dosage form to verify 
it’s in vivo performance. In general, Food and Drug Administration (FDA) accepts 
any innovator’s drug product as a reference standard. The innovator is the one who 
originally received approval from the FDA to market the product in the country. 
Sometime, several manufactures may hold approval for certain drugs. Therefore, 
any one of the permitted drug products can be used as a reference standard. In 
many of these instances, the FDA would request that only of these products be used 
as a reference product in order to obtain a more easily comparable data.
Most of the times orally administered dosage forms are subjected for bioavail-
ability studies. However, dosage forms administered by other routes such as buc-
cal, transdermal, and intramuscular should also be evaluated for their biological 
performance. The therapeutic utility of these dosage forms depends on the rate 
and extent of absorption of the drug from these dosage forms. Orally administered 
dosage forms show a much variation in their performance because of intersubject 
and intrasubject variations.
Subject Treatment for period No.
I II
1 A B
2 B A
3 A C
4 C A
5 A D
6 D A
7 B C
8 C B
9 B D
10 D B
11 C D
12 D C
Table 2. 
Balanced incomplete block design (BIBD) for four formulations.
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2.5 Single versus multiple dose study design
If the dosage forms are to be evaluated only for bioequivalence purposes, 
single dose studies are sufficient. This is because the relative bioavailability of 
most tablets and capsules can be determined on a single dose basis and usually 
this is predictive of multiple dose levels. Dosage forms determined for a single 
dose administration for a therapeutic benefit such as analgesic for the relief of 
head ache needs only single dose studies [19]. However, certain dosage forms 
designed to achieve special release profiles of drugs may require multiple dose 
studies like time release products, enteric-coated preparations, and some intra-
muscular injections. Even the drugs that undergo the first pass metabolism do 
need a multiple dose study.
2.6 Administration of drug products and sampling
Administration of drug products or formulations to the subjects should be 
based on randomization. After the administration, blood samples are withdrawn 
from the subjects at fixed time intervals. Some time is taken to withdraw a sample 
from each subject, and the total time difference between first subject and the last 
subject may range from 10 to 20 minutes depending upon the number of subjects 
and technicians involved in the study. If the sampling schedule is not followed 
rigorously in the same sequential manner, significant differences can conceivably 
exist in the actual duration of the drug in the body and the stated sampling time 
given for each subject. This 10 to 20 min difference in sample withdrawal from 
each subject during the study would represent a substantial change in the drug 
concentrations observed in the blood if under these conditions treatments are 
administered to the subjects in a sequential manner [20, 21].
If the bioavailability of a given dosage form is to be evaluated by a blood level 
study, some estimate of the area under the serum concentration versus time curve, 
peak plasma concentration (Cmax), and time of peak plasma concentration (Tmax) 
must be obtained from the study. Therefore, the frequency of sampling and the 
duration of sampling are very important for study. It will vary with the drug. There 
must be sufficient sampling points to allow for proper evaluation of the area under 
the blood level curve. A blood sampling done up to three to five half-lives of the 
drug, and if the half-life of the drug is not known, blood sampling should proceed 
until 1/10 or 1/20 of the peak levels are reached.
Urinary excretion studies are used when it is either not possible to measure a 
given drug in the blood, plasma or serum or when ethical considerations do not 
allow the collection of samples over a period of time. The advantage of this method 
is it involves noninvasive method of sampling, concentration of the drug in the 
urine is often greater than serum and the amount of the drug excreted in urine is 
obtained directly. But it is not useful in estimating the absorption rate of rapidly 
absorbed drugs and sometimes metabolites may interfere with the estimation of the 
unchanged drug in the urine sample.
Sampling must be continued for a sufficient time period to ensure that the area 
extrapolated from the time of the last measured concentration to infinite time 
should be less than 20% of the total AUC. AUC calculations are not useful in case 
of enterohepatic recycling where the terminal elimination rate constant cannot be 
calculated accurately. In such case, at least three sampling points from absorption 
phase, three to four points from Tmax and four points during the elimination phase 
has been taken. Intervals between successive sampling points in terminal elimina-
tion phase are used to calculate the elimination rate constant. It should not be longer 
than the half-life of the study drug.
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2.7 Selection of the number of subjects
The number of subjects should be sufficient in the study to allow for possible 
withdrawals or dropouts. In initial study, it is acceptable to replace a subject with-
drawal or dropout once it has provided the substituted subject follows the same 
protocol originally intended for the withdrawn subject and subject is tested under 
similar conditions. The number of subjects involved in a study is determined by the 
following considerations:
1. The level of significant should be 0.05
2. The error variance associated with the primary characteristics to be studied as 
estimated from a pilot experiment, from previous studies
3. The expected deviation from the reference drug compatible with 
bioequivalence
4. The required power, normally >80% to detect the maximum allowable differ-
ence in primary characteristics to be studied
2.7.1 Selection criteria for subjects
The studies should be performed on healthy adult volunteers with the aim to 
minimize variability between the study drugs. Subjects may be males or females; 
however, the choice of gender should be consistent with usage and safety criteria of 
the drug. To minimize intra and intersubject variation, the study design should be 
standardized as much as possible and acceptable.
2.7.2 Fasting and fed state considerations
Generally, a single dose study should be conducted after an overnight fast (at 
least 10 hours) and subsequent fasting of 4 hours after administration dosing. For 
multiple dose studies, 2 hours of fasting before and after the dose are acceptable. 
Estimation of Cmax and Tmax for the modified release products or drug is given with 
food in such case fed state studies also been carried out in addition to the normal 
fasting state bioavailability studies [22]. During fed state studies, the consumption 
of a high fat breakfast of 950–1000 KCals is required before dosing. The food intake 
containing at least 50% of these calories must come from fat, 15–20% calories from 
proteins, and the remaining from carbohydrates. A single standard diet should be 
followed taking into consideration of all the Indian subcontinent people. The high 
fat breakfast must be consumed approximately 15 minutes before dosing in fed state 
condition.
2.8 Study conditions
Study conditions such as study environment, diet, fluid intake, post dosing 
postures, exercise, sampling schedules, etc. are monitored during studies. These 
conditions are stated in the protocol, and at the end of the study, these should be 
complied, to assure that all variability factors involved in the study to minimize the 
products to be tested. Least 48 hours before commencement, the study subjects 
abstain from smoking, drinking alcohol, xanthine containing foods, coffee, tea and 
beverages, and fruit juices.
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2.9 Steady state studies
Steady state study is considered in the following conditions:
1. The drug has a long terminal elimination half-life
2. Blood concentrations after a single dose cannot be achieved for a sufficient 
time.
3. For drugs, which are toxic or have adverse effects that are ethically should 
not be administered to patients but they are a necessary part of therapy 
(cytotoxics).
4. For modified release products or sustained release products which assess the 
fluctuation in plasma drug concentration at steady state.
5. Where the drug is likely to accumulate in the body.
6. For drugs that exhibit nonlinear, that is, dose or time dependent 
pharmacokinetics.
7. For combination products where the ratio of plasma concentration of the 
individual drugs is important.
8. For those drug which induce their own metabolism
9. For enteric coated preparations where the coating is innovative.
2.10 Analysis of biological samples
Ideally, the biological samples collected as per the sampling procedure have 
to be analyzed immediately after the study but most of the times the samples 
are stored for several days before subjected to analysis. During storage, the drug 
may undergo a chemical degradation, adsorption on the walls of the container, 
etc., so storage of plasma samples is an important aspect of bioavailability 
studies. The analytical method used for the estimation of the active ingredient 
responsible for the therapeutic efficacy must be selective and sensitive. Drugs, 
that undergo the first pass effect exhibit different unchanged drug/metabolite 
ratio depending on the rate of absorption. In the analysis of blood and urine, the 
major problem is to extract quantitatively and then separate the intact drug from 
its major metabolites or even to separate a mixture of two or more drugs from 
their metabolite.
2.11 Methods of assessment of bioavailability
Pharmacokinetic methods are used for the assessment of bioavailability of 
drug products that exists as a linear relation between the drug level in the biologi-
cal fluid and therapeutic response. Therefore, these methods are also known 
indirect methods. Because therapeutically active drug can be accurately measured 
in biological fluids, plasma and urine data give the most objective information on 
bioavailability [23].
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2.11.1 Indirect methods or pharmacokinetic methods
Plasma data are most widely used and accepted method for the assessment of 
bioavailability of the drug product. The basic assumption in this method is that 
drug products that are bioequivalent product super imposable plasma level time 
curve. The parameters Tmax and Cmax are the measures of the rate of absorption of 
the drug, while the parameters AUC is a measure of the extent of absorption.
Urinary excretion method is based on the general observation that the rate of 
urinary excretion of a drug is directly proportional to the concentration of the drug 
in the blood. Therefore, the bioavailability can be calculated as the ratio of the total 
amount of the unchanged drug recovered in urine following the administration of 
test and standard formulations. Urinary metabolite excretion data are not used for 
the estimation of bioavailability since the drug can undergo metabolism at different 
sites including the gut and liver, and the rates of metabolism may vary because of 
various reasons.
The relative bioavailability should lie within an acceptance range of 0.80–1.25 if 
90% confidence interval is considered. In case of an especially narrow therapeutic 
range, the acceptance range may need to be tighter. In rare cases such as highly 
variable drugs, a wider acceptance range may be acceptable if it has right clinical 
justification. Cmax ratio is the measure of relative bioavailability that may be more 
variable than the AUC ratio, and a wider acceptance range may be acceptable. 
The range used in the protocol should be justified taking into account safety and 
efficacy consideration. Tmax is a measure of release or action or signs for a relation 
to adverse effects.
2.11.2 Direct methods or pharmacodynamic methods
The pharmacodynamic methods are used when assessment of bioavailability 
by pharmacokinetic methods is not possible due to nonavailability of a sensitive 
analytical method for the measurement of the drug or the analytical methods lacks 
sufficient accuracy and/or reproducibility. The two pharmacodynamic methods 
used for the estimation of bioavailability are based on the measurement of acute 
pharmacological effect and clinical response. In order to estimate the bioavailability 
of a drug product accurately by measurement of acute pharmacological effect, 
the following criteria should meet. These are an easily measurable response such 
as heart rate, ECG, blood pressure, pupil diameter, etc. and an established dose-
related response curve.
2.12 Statistical analysis of the data and analysis of variance (ANOVA)
Due to biological and experimental variations, some differences always exist, 
and it is necessary to ascertain whether these differences are simply chance occur-
rences or are due to actual differences in treatment administered to the subjects. 
Statistical methods are used to evaluate the pharmacokinetic data in order to iden-
tify the different sources of variation and if possible to measure the contribution 
of each identified variable and isolate the specific observation of primary interest. 
The analysis of variance (ANOVA), a statistical procedure that used for a crossover 
design is widely used method in bioavilability testing [24].
The pharmacokinetic parameters derived from blood drug concentration and 
time from bioavailability studies are subjected to ANOVA. In ANOVA, the vari-
ance is due to subjects, periods, and treatment. The classical null hypothesis test is 
considered where H0: μT = μR if the pharmaceutical products are bioequivalent and 
alternate hypothesis therefore is H1: μT ≠ μR where products are bioinequivalent 
11
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where μT and μR are the expected mean bioavailability of the test and reference or 
standard drug, respectively.
Bioavailability studies are designed in two ways, and these are design 1 and 
design 2. Design 1 is parallel design in which the subjects divide into two treatment 
groups and assign one treatment to each group. Design 2 is crossover design in 
which each subject has one block and applies both the treatments to each subject 
with washout period in between them. In a parallel design, variability due to the 
treatment is considered, and in the crossover design, variability due to treatment, 
subject, and period are considered to minimize variability. Error sum of squares in 
design 1 (SSE1) and sum of error sum of squares in design 2 (SSE2) are equal. The 
error mean sum of square for design 1 (MSE1) will be greater than the error mean 
sum of square for design 2 (MSE2) if the degrees of freedom for SSE are the same in 
the both designs then error variability is greater in the parallel group design com-
pared to the crossover design (Tables 3 and 4).
The mean sum of squares is compared with the mean sum of squares due to 
error (F = MST/MSE), and if these are comparable, no difference between the 
levels of a factor is concluded, otherwise a difference is achieved. The treatment 
mean sum of squares is larger than the error mean sum of squares if difference is 
achieved between the treatments. Then the chances of getting treatment mean sum 
of squares being bigger than the error mean sum of squares are more in design 2 
compared to design 1. Therefore, chances of showing a statistically significant dif-
ference are higher in design 2 compared to design 1. This is equivalent to saying that 
design 2 is more competent than design 1. Null hypothesis H0 μT = μR provides an 
assessment amount of drug absorbed from the test product is identical or equal or 
similar to the amount of drug absorbed from the reference. They may be different 
or nearly equal but not identical in most of the cases. If the trial is run under tightly 
controlled conditions and the number of subjects is large enough, no matter how 
small the difference between the formulations and it will be detected as signifi-
cant. The difference may give rise to following anomalies due to a large difference 
between two formulations, sample size not large enough (Table 5).
In some cases, simple null hypothesis was inappropriate and alternative 
approach to ANOVA for bioequivalence studies is considered as Type I and II error. 
Type I error is a manufacturer’s risk that is explained by probability of rejecting a 
formulation which is in fact bioequivalent. Manufacturer’s risk is the probability 
(α = 0.05) of rejecting H0 when H0 is true. Similarly, type II error is the consumer’s 
risk that is explained as the probability (β) of accepting a formulation which is 
bioinequivalent that is accepting H0 when H0 is false. FDA restricts the power of 
the test which should be 80% and the consumer’s risk β to 20%, but this may not a 
satisfactory solution for either the consumer or the regulatory agencies. It makes 
Sources of variance Degree of freedom (D F) Sum of squares (SS) Mean of squares (MS) F statistic
Treatment T-1 SST MST MST/MSE
Subjects N-1 SSS MSS MSS/MSE
Period T-1 SSP MSP MSP/MSE
Error (T-1)(N-2) SSE MSE
Total Tn-1
T is the number of treatments, SST-sum of squares due to treatments, SSP-sum of squares due to period, MSS-mean 
sum of squares due to subjects, MST-mean sum of squares due to treatments, MSP-mean sum of squares due to period, 
and N is the number of subjects.
Table 3. 
Analysis of variance (ANOVA) table for t-period, t-treatment crossover design.
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sense that the regulatory authorities should control the consumer’s risk and let 
the pharmaceutical company decide how much manufacturer’s risk they are will-
ing to accept. According to FDA guidelines for bioavailability studies state that 
“Products whose rate and extent of absorption differ by 20% or less are generally 
bioequivalent.” The main object of bioequivalence studies is not in testing the null 
hypothesis of equality but to assess the difference between in two treatments groups 
and bioequivalence studies of two formulations is concluded that the difference is 
within 20% of the reference mean.
2.13 Characteristics to be investigated during bioequivalence studies
Evaluation of bioavailability and bioequivalence studies will be based upon the 
measurement of concentrations of the active drug substances in the plasma with 
respective of time. In some situations, the measurements of an active or inactive 
metabolite may be necessary. These situations include where the concentrations 
of the drugs may be too low to accurately measure in the biological matrix, limita-
tions of the analytical method, unstable drugs, and drugs with a very short half-
life. Racemates should be measured by an achiral assay method. Measurement of 
individual enantiomers in bioequivalence studies is required where they exhibit 
different primary efficacy, safety activity, pharmacodynamic and pharmacokinetic 
characteristics with the minor enantiomer. The pharmacokinetic parameters for 
product are Cmax, Tmax, AUC0-t, and AUC0-∞ and for steady state are AUC0-τ, Cmax, 
Cmin, and degree of fluctuation should be calculated from the plasma time concen-
tration profile.
2.14 Bioavailability and bioequivalence testing
Bioavailability and bioequivalence testing are carried out for two formulations 
such as new and commercially marketed brand drug [25]. These studies are con-
ducted by experimental designs such as parallel and cross over design in healthy 
Sources of variance Degree of freedom (DF) Sum of squares (SS) Mean of squares (MS) F statistic
Between Treatments 1 SST2 MST2 MST2/MSE2
Subjects N-1 SSS2 MSS2
Between Period 1 SSP2 MSP2
Errors N-2 SSE2 MSE2
Total 2N-1
Table 5. 
Design 2A comparison of ANOVA for parallel group design and 2-treatment, 2-period crossover design  
with n subjects.
Sources of variations Sum of squares (SS) Degree of freedom (DF) Mean sum of squares (MSS) F statistic
Between treatments SST1 1 MST1 MST1/
MSE1
Error SSE1 N-2 MSE1
Total N-1
Table 4. 
Design 1 A comparison of ANOVA for parallel group design and 2-treatment, 2-period crossover design  
with n subjects.
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volunteer subjects but occasionally in patients. After administration of formulation 
under standard study conditions, plasma samples are withdrawn at regular time 
intervals and assayed for parent drug or occasionally metabolite concentration 
in plasma or urine. In some cases, concentration of drug in the blood is neither 
feasible nor possible to compare. Plasma concentration data are used to determine 
the pharmacokinetic parameters such as AUC, Cmax, Tmax, and absorption lag time 
(Tlag). Bioavailability studies should be conducted at different doses, especially 
when the drug follows nonlinear pharmacokinetics. In addition to a data from 
bioequivalence studies, other data may need to be submitted for evidence to meet 
regulatory requirements for bioequivalence includes analytical method validation 
and in vitro-in vivo correlation studies.
2.15 Criteria for bioequivalence
A 90% confidence interval is considered to establish bioequivalence for AUC, 
Tmax, and Cmax which should fall within the range of 80–125%. A 5% level of 
significance is taken for rejection of one sided t-test with the null hypothesis of 
bioequivalence. In bioavailability studies, closer limits are considered for drug that 
have a narrow therapeutic index, serious dose-related toxicity, steep dose, effect 
curve, and nonlinear pharmacokinetics within the therapeutic dose range. A wider 
acceptance range may be admissible if it is based on sound clinical justification. In 
case of suprabioavailability, a reformulation of the drug product is required and 
again bioequivalence study has to be carried out. Application of new formulation is 
required to support the clinical trial data especially for dosage recommendations. 
Such formulations are usually not being accepted as therapeutically equivalent to 
the existing reference drug.
3. Regulatory definitions
3.1 Australia
The Therapeutics Goods Administration (TGA) considers two formulations 
to be bioequivalent if the ratios between the two formulations of Cmax and AUC 
should lie in the range of 0.80–1.25 and Tmax should also be similar between the two 
formulations [25]. There are closer limits for drugs with a narrow therapeutic index 
and saturable metabolism. Thus, no generic drug formulations exist in for digoxin 
or phenytoin for instance in the Australian market.
3.2 Europe
European Economic Area considers two formulations to be bioequivalent if 
they have pharmaceutically equivalency and their bioavailabilities are similar after 
administration in the same molar dose with respect to both efficacy and safety. For 
bioequivalence of two dosage forms, 90% confidence intervals are considered as 
Australia.
3.3 United States
In case of FDA, two formulations are bioequivalent if the 90% confidence 
interval of the relative mean of Cmax, AUC0-t, and AUC0-∞ of the test or generic 
formulation should be within 80–125% in the fasting state. Sometimes, fed 
state bioequivalent comparison studies were carried out for test to reference 
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formulations where required to administer the formulations after an appropri-
ate meal at a specified time before taking the drug to know the food effect. 
Food effect study requires the same statistical evaluation as the fasting study as 
described above.
4. Importance of bioavailability and bioequivalence studies
4.1 Universal approach about comparative bioavailability
Most bioavailability studies, whether for a new or generic product, are carried 
out for the common theme. These studies are conducted to identify the quantitative 
nature of a specific product comparison. The absolute bioavailability of new drug 
is used to assess the pharmacokinetic parameters of an oral formulation relative to 
that of an intravenous dose or performance of a modified release formulation in 
comparison to a conventional capsule. For a generic product, it is mainly done for 
comparison of a competitive formulation with a reference or standard drug. Such 
commonality in comparative bioavailability studies suggests a universal experimen-
tal approach.
4.2 Comparative bioavailability studies of new drugs (NDA)
Comparative bioavailability studies for new drug are used to conduct to deter-
mine the bioavailability and bioequivalence of the formulation in humans for safety 
and efficacy. Information about bioavailability of new drug formulation is obtained 
by comparing the pharmacokinetics parameters of an intravenous and oral admin-
istration of new drug formulations having the same dose [26].
4.3 Comparative bioavailability of generic drugs (ANDA)
When a manufacturer wishes to gain therapeutic equivalence for introducing a 
competitive generic product into the market place, it is not necessary to conduct the 
full batch of clinical trials needed for the first product. If therapeutic equivalence 
has been determined, study has to be carried out according to prescribed study 
requirements, and it should be similar or equivalent to the previous or innova-
tor product. This is regarded as therapeutically equivalent to the innovative drug 
product [27].
4.4 Testing under fasting conditions or fed conditions
When the particular drug is not showing any expected results under fasting con-
ditions, then the drug can also be tested under fed conditions to meet all conditions 
as per regulatory norms in bioequivalence studies.
5. Conclusion
The concept of bioavailability and bioequivalence studies has been adopted by 
the pharmaceutical industry and national regulatory authorities throughout the 
world over 20 years. It is mainly due to increasing the number of generic drugs 
and its formulations and marketed after regulatory acceptance. So, the bioavail-
ability and bioequivalence studies carried under stringent protocols and modified 
according to the needs. Pharmacokinetic parameters are evaluated by the statistical 
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methods to get accurate results to assure high quality interchangeable and afford-
able drugs. There is a continuing attempts made by different organizations, authori-
ties, and basic scientists to understand and develop more efficient and scientific 
valid approaches to evaluate bioavailability and bioequivalence studies of various 
formulations.
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